- Home
- RLMD vs EDIT Comparison
RLMD vs EDIT Comparison
Compare RLMD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- EDIT
- Stock Information
- Founded
- RLMD 2004
- EDIT 2013
- Country
- RLMD United States
- EDIT United States
- Employees
- RLMD N/A
- EDIT N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RLMD Health Care
- EDIT Health Care
- Exchange
- RLMD Nasdaq
- EDIT Nasdaq
- Market Cap
- RLMD 289.7M
- EDIT 269.8M
- IPO Year
- RLMD N/A
- EDIT 2016
- Fundamental
- Price
- RLMD $3.98
- EDIT $2.60
- Analyst Decision
- RLMD Hold
- EDIT Buy
- Analyst Count
- RLMD 2
- EDIT 10
- Target Price
- RLMD $1.00
- EDIT $4.13
- AVG Volume (30 Days)
- RLMD 1.8M
- EDIT 2.5M
- Earning Date
- RLMD 11-13-2025
- EDIT 11-10-2025
- Dividend Yield
- RLMD N/A
- EDIT N/A
- EPS Growth
- RLMD N/A
- EDIT N/A
- EPS
- RLMD N/A
- EDIT N/A
- Revenue
- RLMD N/A
- EDIT $46,383,000.00
- Revenue This Year
- RLMD N/A
- EDIT N/A
- Revenue Next Year
- RLMD N/A
- EDIT N/A
- P/E Ratio
- RLMD N/A
- EDIT N/A
- Revenue Growth
- RLMD N/A
- EDIT N/A
- 52 Week Low
- RLMD $0.24
- EDIT $0.91
- 52 Week High
- RLMD $4.34
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- RLMD 78.00
- EDIT 37.49
- Support Level
- RLMD $2.42
- EDIT $2.42
- Resistance Level
- RLMD $2.86
- EDIT $2.80
- Average True Range (ATR)
- RLMD 0.43
- EDIT 0.21
- MACD
- RLMD 0.15
- EDIT -0.06
- Stochastic Oscillator
- RLMD 82.19
- EDIT 25.12
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.